# 2026-16711: FDA Okays Master Files for Forever-Editing Animal DNA – Gattaca for Pets?

2026-16711, Type VII Veterinary Master File for Research and Development and Risk Reviews; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-17, effective 2026-08-17 (as of 2026-08-24).

- Canonical: https://policyrisk.com/federal-register/2026-16711
- As of: 2026-08-24
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16711
- Title: Type VII Veterinary Master File for Research and Development and Risk Reviews; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53257
- Published: 2026-08-17
- Effective: 2026-08-17
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-24

## In one line

FDA Okays Master Files for Forever-Editing Animal DNA – Gattaca for Pets?

## Summary

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #260 entitled "Type VII Veterinary Master File for Research and Development and Risk Reviews." This guidance describes FDA's current thinking regarding the use of Type VII Veterinary Master Files (Type VII VMFs). Type VII VMFs are appropriate for research and development of animal cells, tissues, and cell- and tissue-based products (ACTPs), gene therapies, and heritable intentional genomic alterations (IGAs) in animals.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16711 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/17/2026-16711/type-vii-veterinary-master-file-for-research-and-development-and-risk-reviews-guidance-for-industry)
- [2026-16711 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-17/pdf/2026-16711.pdf)

## Related
- [Previous: 2026-16710, Distribution of Satellite Royalty Funds](https://policyrisk.com/federal-register/2026-16710)
- [Next: 2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-16712)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16711 (as of 2026-08-24).
